Annual Total Long Term Liabilities
$72.77 M
+$32.30 M+79.81%
December 31, 2023
Summary
- As of February 7, 2025, GALT annual total long term liabilities is $72.77 million, with the most recent change of +$32.30 million (+79.81%) on December 31, 2023.
- During the last 3 years, GALT annual total long term liabilities has risen by +$72.76 million (+909462.50%).
- GALT annual total long term liabilities is now at all-time high.
Performance
GALT Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$96.19 M
+$1.01 M+1.06%
September 30, 2024
Summary
- As of February 7, 2025, GALT quarterly total long term liabilities is $96.19 million, with the most recent change of +$1.01 million (+1.06%) on September 30, 2024.
- Over the past year, GALT quarterly long term liabilities has increased by +$33.68 million (+53.88%).
- GALT quarterly long term liabilities is now at all-time high.
Performance
GALT Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
GALT Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +79.8% | +53.9% |
| 3 y3 years | +10000.0% | +369.5% |
| 5 y5 years | +100.0% | +10000.0% |
GALT Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +141.1% | at high | +218.8% |
| 5 y | 5-year | at high | >+9999.0% | at high | -100.0% |
| alltime | all time | at high | -100.0% | at high | -100.0% |
Galectin Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $96.19 M(+1.1%) |
| Jun 2024 | - | $95.19 M(+12.9%) |
| Mar 2024 | - | $84.34 M(+15.9%) |
| Dec 2023 | $72.77 M(+79.8%) | $72.77 M(+16.4%) |
| Sep 2023 | - | $62.51 M(+2.1%) |
| Jun 2023 | - | $61.26 M(+19.3%) |
| Mar 2023 | - | $51.34 M(+26.9%) |
| Dec 2022 | $40.47 M(+34.1%) | $40.47 M(+32.0%) |
| Sep 2022 | - | $30.66 M(+1.5%) |
| Jun 2022 | - | $30.22 M(-0.2%) |
| Mar 2022 | - | $30.27 M(+0.3%) |
| Dec 2021 | $30.18 M(>+9900.0%) | $30.18 M(+47.3%) |
| Sep 2021 | - | $20.49 M(+100.2%) |
| Jun 2021 | - | $10.23 M(>+9900.0%) |
| Mar 2021 | - | $0.00(-100.0%) |
| Dec 2020 | $8000.00(-84.6%) | $8000.00(-57.9%) |
| Sep 2020 | - | $19.00 K(-38.7%) |
| Jun 2020 | - | $31.00 K(-26.2%) |
| Mar 2020 | - | $42.00 K(-19.2%) |
| Dec 2019 | $52.00 K(>+9900.0%) | $52.00 K(-16.1%) |
| Sep 2019 | - | $62.00 K(-13.9%) |
| Jun 2019 | - | $72.00 K(-11.1%) |
| Mar 2019 | - | $81.00 K(>+9900.0%) |
| Dec 2018 | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2018 | - | $0.00(0.0%) |
| Jun 2018 | - | $0.00(0.0%) |
| Mar 2018 | - | $0.00(0.0%) |
| Dec 2017 | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2017 | - | $0.00(0.0%) |
| Jun 2017 | - | $0.00(0.0%) |
| Mar 2017 | - | $0.00(0.0%) |
| Dec 2016 | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2016 | - | $0.00(0.0%) |
| Jun 2016 | - | $0.00(0.0%) |
| Mar 2016 | - | $0.00(0.0%) |
| Dec 2015 | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2015 | - | $0.00(0.0%) |
| Jun 2015 | - | $0.00(0.0%) |
| Mar 2015 | - | $0.00(0.0%) |
| Dec 2014 | $0.00 | $0.00(0.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2014 | - | $0.00(0.0%) |
| Jun 2014 | - | $0.00(0.0%) |
| Mar 2014 | - | $0.00(0.0%) |
| Dec 2013 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sep 2013 | - | $1000.00(-80.0%) |
| Jun 2013 | - | $5000.00(0.0%) |
| Mar 2013 | - | $5000.00(-16.7%) |
| Dec 2012 | $6000.00(>+9900.0%) | $6000.00(-99.9%) |
| Sep 2012 | - | $6.69 M(+0.9%) |
| Jun 2012 | - | $6.64 M(+0.9%) |
| Mar 2012 | - | $6.58 M(>+9900.0%) |
| Dec 2011 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sep 2011 | - | $6.46 M(+0.1%) |
| Jun 2011 | - | $6.46 M(+0.8%) |
| Mar 2011 | - | $6.41 M(+2.9%) |
| Dec 2010 | $6.22 M(+61.6%) | $6.22 M(+23.4%) |
| Sep 2010 | - | $5.04 M(+2.0%) |
| Jun 2010 | - | $4.94 M(-5.0%) |
| Mar 2010 | - | $5.20 M(+35.1%) |
| Dec 2009 | $3.85 M(+3996.8%) | $3.85 M(+1.1%) |
| Sep 2009 | - | $3.81 M(+13.9%) |
| Jun 2009 | - | $3.35 M(+65.3%) |
| Mar 2009 | - | $2.02 M(+2053.2%) |
| Dec 2008 | $94.00 K(-95.5%) | $94.00 K(-89.6%) |
| Sep 2008 | - | $908.00 K(-55.8%) |
| Jun 2008 | - | $2.06 M(-65.8%) |
| Mar 2008 | - | $6.02 M(+185.7%) |
| Dec 2007 | $2.11 M(+431.8%) | $2.11 M(-0.8%) |
| Sep 2007 | - | $2.12 M(+134.7%) |
| Jun 2007 | - | $905.00 K(-66.5%) |
| Mar 2007 | - | $2.71 M(+583.1%) |
| Dec 2006 | $396.00 K(>+9900.0%) | $396.00 K(-82.8%) |
| Sep 2006 | - | $2.30 M(-56.3%) |
| Jun 2006 | - | $5.26 M(-47.0%) |
| Mar 2006 | - | $9.92 M(+9756.9%) |
| Jun 2002 | - | $100.60 K(>+9900.0%) |
| Mar 2002 | - | $0.00(0.0%) |
| Dec 2001 | $0.00 | $0.00(-100.0%) |
| Sep 2001 | - | $195.00 K(-85.1%) |
| Jun 2001 | - | $1.31 M |
FAQ
- What is Galectin Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Galectin Therapeutics?
- What is Galectin Therapeutics annual total long term liabilities year-on-year change?
- What is Galectin Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly long term liabilities year-on-year change?
What is Galectin Therapeutics annual total long term liabilities?
The current annual total long term liabilities of GALT is $72.77 M
What is the all time high annual total long term liabilities for Galectin Therapeutics?
Galectin Therapeutics all-time high annual total long term liabilities is $72.77 M
What is Galectin Therapeutics annual total long term liabilities year-on-year change?
Over the past year, GALT annual total long term liabilities has changed by +$32.30 M (+79.81%)
What is Galectin Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of GALT is $96.19 M
What is the all time high quarterly long term liabilities for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly total long term liabilities is $96.19 M
What is Galectin Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, GALT quarterly total long term liabilities has changed by +$33.68 M (+53.88%)